Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Quanterix introduces new Simoa 2.0 utrasensitive immunoassay platform

Quanterix has introduced next-generation ultrasensitive immunoassay platform, Simoa 2.0, which includes multiple improvements to assay performance, hardware and software refinements and overall instrument usability.

Simoa platform uses single molecule measurements to access previously undetectable proteins, and provides significant benefits to both research and clinical testing applications.

The company will provide Simoa 2.0 improvements to all of its current customers with a simple upgrade procedure.

The new improvements include multiple hardware and software advances, as well as comprehensive training program that will enable customers to improve overall performance, reliability and ease of use.

Quanterix CEO and executive chairman Kevin Hrusovsky said: "We have experienced rapid adoption of Simoa since our launch last year and have listened carefully to our customers’ feedback on our ‘game changing’ fully-automated, ultrasensitive protein detection platform.

"Based on feedback, we have made an unprecedented investment to further improve the platform, including increasing assay robustness, improving multiplex capabilities, reducing sample size and enhancing overall usability of the technology."

In June this year, Quanterix commercially introduced multiplex panels, which allows users to develop their own multiplex assays using the company’s ultra-sensitive Simoa technology.

The firm also launched multiplex homebrew kit that enables users to use their own antibody pairs to develop custom multiplex Simoa panels.